Zheng-Lin Binbin, Bekaii-Saab Tanios S
Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
Division of Hematology and Medical Oncology, Mayo Clinic, 5881 East Mayo Blvd, Phoenix, AZ 85054, USA.
Ther Adv Med Oncol. 2024 Jan 18;16:17588359231225037. doi: 10.1177/17588359231225037. eCollection 2024.
Colorectal cancer is a leading cause of cancer-related mortality worldwide. Approximately 3-5% of colorectal tumors harbor human epidermal growth factor receptor () amplification which is associated with a higher incidence of intracranial metastasis and overall worse outcomes. In the setting of refractory metastatic wild-type tumors, evidence supports the use of various HER2-blocking agents, including monoclonal antibodies, tyrosine kinase inhibitors, and novel antibody-drug conjugates. With a number of relatively active agents clinically available and even more in development, it is crucial for clinicians to familiarize themselves with the mechanisms of action, efficacy data, and safety profiles of these treatments. In this review, we aim to summarize key findings from past and ongoing trials with anti-HER2 agents in metastatic colorectal cancer.
结直肠癌是全球癌症相关死亡的主要原因。约3%-5%的结直肠癌肿瘤存在人表皮生长因子受体（HER2）扩增，这与颅内转移发生率较高及总体预后较差相关。在难治性转移性野生型肿瘤的情况下，有证据支持使用多种HER2阻断剂，包括单克隆抗体、酪氨酸激酶抑制剂和新型抗体-药物偶联物。鉴于临床上有多种相对有效的药物可供使用，且还有更多药物正在研发中，临床医生熟悉这些治疗方法的作用机制、疗效数据和安全性概况至关重要。在本综述中，我们旨在总结既往及正在进行的抗HER2药物治疗转移性结直肠癌试验的主要发现。
